<DOC>
	<DOCNO>NCT00731250</DOCNO>
	<brief_summary>This study design look affect SB-705498 rhinitis symptom , induce capsaicin challenge</brief_summary>
	<brief_title>A Study To Assess The Effect Of SB-705498 In A Capsaicin Challenge Model</brief_title>
	<detailed_description />
	<mesh_term>Rhinitis</mesh_term>
	<mesh_term>Capsaicin</mesh_term>
	<criteria>Healthy . Male female 18 60 year age inclusive . Nonchild bear woman woman child bear potential agree use contraception indicate protocol Nonsmoker least 6 month pack history &lt; 5 pack year ( Pack year = ( No . cigarettes smoked/day/20 ) x No . year smoke ) . Body weight &gt; 50 kg body mass index ( BMI ) within range 19 29.9 kg/m2 ( inclusive ) . Capable give write informed consent . Available complete require study measurement . Normal 12lead ECG screening . For Part 2 : The subject must demonstrate reactivity unilateral , intranasal challenge select single dose capsaicin , define development TSS â‰¥ 3 . Past medical history rhinitis , include allergic , nonallergic rhinitis rhinosinusitis . Nasal condition likely affect outcome study , i.e . nasal septal perforation , nasal polyp , nasal malformation . A history gastrointestinal , hepatic , renal multiple cardiovascular risk factor . Positive prestudy drug/alcohol screen . Positive prestudy Hepatitis B surface antigen positive Hepatitis C antibody result within 3 month screen . A positive test human immunodeficiency virus ( HIV ) antibody ( determined local standard operating procedure ( SOPs ) ) . History regular alcohol consumption within 6 month study . Exposure four new chemical entity within 12 month prior start study . Participation clinical trial new molecule entity clinical trial within 4 month start study . Use prescription nonprescription drug , well vitamin , herbal dietary supplement ( include St John 's Wort ) within 2 day prior study visit Part 1 study 14 day prior first treatment administration Part 2 study . Inability abstain intranasal oral medication treat nasal symptom first capsaicin challenge completion study include : sodium cromoglycate , antihistamine , anticholinergic , alphaadrenergic agonist corticosteroid History drug allergy , opinion Investigator GSK Medical Monitor , contraindicate participation . Subjects demonstrate hypersensitivity placebo capsaicin challenge baseline screening . Donation blood blood product excess 500mL within 56 day period prior start Part 2 study . Pregnant female determine positive serum urine human chorionic gonadotropin ( hCG ) test screen prior dosing . Lactating female . Unwillingness inability follow procedure outline protocol . History sensitivity heparin heparininduced thrombocytopenia . Nicotine level indicative smoke history regular use tobacco nicotinecontaining product within 6 month prior screen . For Part 2 : Subjects know lactose intolerance .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Capsaicin challenge</keyword>
</DOC>